Phase I single- and multiple-ascending dose trial of IMO 8400 in healthy volunteers.

Trial Profile

Phase I single- and multiple-ascending dose trial of IMO 8400 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs IMO 8400 (Primary)
  • Indications Psoriasis; Systemic lupus erythematosus
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Most Recent Events

    • 08 Dec 2014 According to an Idera Pharmaceuticals media release, clinical safety results of this and other trial (see profile 231094) were presented at 56th Annual Meeting of the American Society of Hematology .
    • 07 Aug 2014 Results published in an Idera Pharmaceuticals media release.
    • 30 Jun 2013 Positive results presented at the 3th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), according to an Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top